Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

An osteoanabolic agent should be the first choice treatment for patients at high or imminent risk for fracture, but once ...

An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary ...

For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have ...

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg ...

Faricimab (Vabysmo) showed greater fluid reduction compared with high-dose aflibercept (Eylea) at 12 weeks in matched analyses of diabetic macular edema (DME) and age-related macular degeneration (AMD ...

Aflibercept 2 mg (Eylea, Bayer AG) injections were administered using a prefilled syringe (PFS), following the manufacturer’s indications, with a 30-gauge needle and injecting 0.05 mL of medication (2 ...

(Reuters) -German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge ...

which demonstrated comparable efficacy and safety of Eylea 8 mg with treatment intervals of 3 or 4 months (12 or 16 weeks) compared to standard of care Eylea 2 mg (aflibercept 2 mg) with a fixed ...

which demonstrated comparable efficacy and safety of Eylea 8 mg with treatment intervals of 3 or 4 months (12 or 16 weeks) compared to standard of care Eylea 2 mg (aflibercept 2 mg) with a fixed ...

Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR). EYLEA ® ...